Stockwinners Market Radar for June 30, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:06 EDT Four Corners Property Trust acquires Red Robin Property for $2.4M - Four Corners Property Trust "announces the acquisition of a Red Robin property for $2.4M from the PREIT transaction previously announced in June 2022. The property is located in a strong retail corridor in Maryland and is occupied under a triple net lease to the corporate entity with approximately 4 years of term remaining."

18:34 EDT Zebra Technologies to pay $360M in patent-related settlement with Honeywell - The company states: "On June 28, 2022, Zebra Technologies (ZBRA) and Honeywell International (HON) entered into a license and settlement agreement (the "Agreement") to resolve all patent-related litigation between the Company and Honeywell. Under the Agreement, the Company and Honeywell each deny liability and agreed to a mutual general release from all past claims; entered into a covenant not to sue for patent infringement; agreed to a payment by the Company to Honeywell for past damages of $360 million which will be charged in the Company's second quarter results and will be paid in equal quarterly installments over eight quarters; and entered into a royalty-free cross-license with respect to each party's existing patent portfolio for the lives of the licensed patents. The Agreement also provides for the Company and Honeywell to dismiss all pending IP litigation in U.S. district courts, the U.S. International Trade Commission, and various courts outside the U.S. between the parties."

18:29 EDT Mondelez' Enjoy Life Natural Brands recalls baked snack products - The company states: "Enjoy Life Natural Brands LLC announced today a voluntary recall, out of an abundance of caution, of a limited quantity of a select list of baked snacks products due to the potential presence of hard plastic pieces. The company became aware of this issue as a result of internal quality assurance surveillance. This recall is limited exclusively to the Enjoy Life products and Best By Dates listed in the grid below which are sold in retail stores and online in the United States and Canada. No other Enjoy Life Foods products are affected by this voluntary recall."

18:07 EDT Takeda's Takhzyro reports Phase 3 data of Takhzyro in HAE attacks - Takeda announced late-breaking data from the Phase 3 SPRING study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2022, demonstrating positive results of Takhzyro for preventing hereditary angioedema - HAE - attacks in patients 2 to less than12 years of age, which were consistent with earlier studies in adult and adolescent patients. There are currently no long-term prophylactic treatments approved for HAE patients younger than 6 years. The primary objective of the open-label, multicenter, Phase 3 SPRING study was to evaluate the safety and pharmacokinetics of Takhzyro in patients aged 2 to less than12 years with HAE. Clinical outcomes - prevention of HAE attacks - were measured as a secondary objective. Takhzyro reduced the rate of HAE attacks in children by a mean of 94.8% compared to baseline. 76.2% of patients were attack-free during the 52-week treatment period. No deaths or serious treatment-emergent adverse events were reported during the study, and no patients withdrew from the study due to TEAEs. These results are consistent with the favorable efficacy and safety profile of Takhzyro observed in earlier studies with adult and adolescent patients. These data will be submitted to global regulatory authorities to evaluate a potential label expansion for Takhzyro to include the younger patient population.

17:44 EDT Embraer signs agreement with Toyota do Brasil - Embraer (ERJ) signed an agreement with Toyota do Brasil in order to embrace Toyota Production System principles and concepts in its industrial operations. The initiative aims to eliminate waste, obtain operational efficiency, and increase value generation for stakeholders. During the first phase of this joint work, a team of TPS specialists from Toyota (TM) Brazil will immerse themselves in Embraer's daily work to evaluate and suggest improvements for the company's main manufacturing area at the Ozires Silva Unit, located in Sao Jose dos Campos, Sao Paulo.

17:26 EDT General Electric awarded $112M Navy contract modification - General Electric was awarded a $112M firm-fixed-price modification to a previously awarded contract. This modification exercises an option to procure 24 Lot 26 full rate production F414-GE-400 engines and devices in support of F/A-18 Super Hornet production aircraft for the Navy. Work is expected to be completed in February 2024. FY22 aircraft procurement funds in the amount of $112M will be obligated at time of award, none of which will expire at the end of the current fiscal year. The Naval Air Systems Command is the contracting activity.

17:23 EDT BAE Systems awarded $298.73M Army contract modification - BAE Systems was awarded a $298.73M modification to a contract for the production and delivery of M109A7 and M992A3 vehicles. Work will be performed in York, Pennsylvania, with an estimated completion date of December 31, 2024. FY20 and FY21 procurement of weapons and tracked combat vehicles, Army funds in the amount of $298.73M were obligated at the time of the award. Army is the contracting activity.

17:19 EDT B.Riley buys $1.0M in CalAmp common stock - In a regulatory Form 4 filing, CalAmp disclosed that B. Riley Asset Management bought 225K shares of the company's common stock on June 28th in a total transaction size of $1.0M. Shares of CalAmp are up 3.4% afterhours.

17:03 EDT Skillz appoints Jason Roswig as CFO - Skillz (SKLZ) has hired Jason Roswig as the company's President and CFO. Roswig will join the company on August 8, 2022 from Blackstone (BX), where he served as Managing Director. He will replace the current Skillz CFO, Ian Lee, who is stepping down to pursue other opportunities. Formerly Managing Director in Blackstone's Private Equity and Portfolio Operations groups, Roswig had oversight of the financial and operating performance of Blackstone's technology portfolio. Prior to that, he served as an Expert Associate Partner in McKinsey & Company's Corporate Finance and Organization practices.

16:52 EDT Apple's former director of corporate law admits to insider trading - The Department of Justice, U.S. Attorney's Office, District of New Jersey, made a statement that said in part: The former corporate secretary and director of corporate law at Apple admitted engaging in an insider trading scheme that spanned five years, Attorney for the United States Vikas Khanna announced. Gene Levoff of San Carlos, California, pleaded guilty by videoconference before U.S. District Judge William J. Martini to six counts of an indictment charging him with securities fraud. Levoff was initially charged by complaint in February 2019... "Gene Levoff betrayed the trust of one of the world's largest tech companies for his own financial gain," Attorney for the United States Khanna said. "Despite being responsible for enforcing Apple's own ban on insider trading, Levoff used his position of trust to commit insider trading in order to line his own pockets. This Office will continue to prioritize securities fraud prosecutions."...From February 2011 to April 2016, Levoff - the top corporate attorney at Apple who also served as the company's assistant secretary and corporate secretary - misappropriated material, nonpublic information about Apple's financial results and then executed trades involving the company's stock. This scheme to defraud Apple and its shareholders allowed Levoff to realize profits of approximately $227,000 on certain trades and to avoid losses of approximately $377,000 on others...The securities fraud counts each carry a maximum penalty of 20 years in prison and a $5M fine. Sentencing is scheduled for Nov. 10.The SEC previously filed a civil complaint against Levoff based on the same conduct. Reference Link

16:47 EDT Orange County Bancorp names Jonathan Rouis board chair - Orange County Bancorp, parent company of Orange Bank & Trust Co. and Hudson Valley Investment Advisors, announced the appointment of Jonathan Rouis as new board chair of both the company's and Bank's board of directors effective June 17th, 2022. He assumes the position held for the past ten years by Lou Heimbach. The company also announced the appointment of Richard Rowley as Chairman of the Board of HVIA effective April 26th, 2022. "Jonathan has been extremely active on the board, serving as Chair of the audit committee as well as a member of the Company's nominating and Corporate Governance, Compensation, and Executive Committees," said Lou Heimbach. "Jonathan's experience makes him uniquely qualified for this appointment and I look forward to continuing my board service under his leadership." Mr. Heimbach, who has been on the board since 1990, will continue as a Director of the Company.

16:33 EDT Micron projects sequential bit shipments to be down for DRAM, NAND in Q4 - Says expects the impact of actions to be limited in Q4 and to become more material in FY23. Says supply chain challenges and COVID-19 control measures in China impacted business on both the demand and supply side. Says 1-beta node is on track to ramp in manufacturing by the end of calendar 2022. Says making excellent progress on 232-layer node and expect to ramp production by the end of calendar 2022. Says continues to expect cost reductions to outpace those of the industry this year. Says PC unit sales now expected to decline by nearly 10% in 2022. Says several customers are adjusting their inventories, and expect these adjustments to take place mostly in the second half of calendar 2022. Says expects year-over-year calendar 2022 industry bit demand growth to be below the long-term CAGRs of mid-to-high-teens percentage for DRAM and high-20s percentage for NAND. Says planning for a reduced level of bit supply growth in FY23. Says now expects FY23 wafer fab equipment capex to decline year over year. Comments taken from Q3 prepared remarks.

16:31 EDT JetBlue extends $30 per share tender offer for Spirit Airlines to July 29 - JetBlue (JBLU) announced that its direct wholly owned subsidiary, Sundown Acquisition Corp. has extended the expiration date of the previously announced tender offer to purchase all of the outstanding shares of common stock per share of Spirit Airlines, Inc. (SAVE) for $30.00 per share, net to the seller in cash, without interest and less any required withholding taxes, to 5:00 p.m., New York City time, on July 29, 2022, unless further extended. The tender offer was previously set to expire at 5:00 p.m., New York City time, on June 30, 2022. All other terms and conditions of the tender offer remain unchanged.

16:26 EDT PureCycle CEO Mike Otworth to resign, Dustin Olson promoted to CEO - PureCycle Technologies announced three key leadership changes effective August 5, 2022. Mike Otworth, Chairman of the Board of Directors and CEO of PureCycle, will resign to return to Innventure, a company he helped found. Dustin Olson, PureCycle's current Chief Operating Officer and Chief Manufacturing Officer, is being promoted to the role of CEO and joining the Board of Directors effective August 5, 2022. Olson has been with PureCycle since 2021 leading manufacturing and operations. Dan Coombs, current member of PureCycle's Board of Directors, will be appointed, upon Mike's departure, to a newly created position of Executive Chairman of the Board of Directors. Mike Otworth said, "I am an entrepreneur at heart, and am excited to see PureCycle's progress over the last seven years. Taking PureCycle from an early concept to a publicly traded company has been an honor. We successfully added deep operational experience to our Board and management team to drive the execution of our business plan. Dustin has proven to be effective, eager, and has unprecedented work ethic. Dustin will lead this team and company into the next phase and will make PureCycle teams past and present proud."

16:21 EDT Visa CEO sells $1.76M in common stock - In a regulatory filing, Visa disclosed that its CEO Alfred Kelly sold 9K shares of common stock on June 30th in a total transaction size of $1.76M as part of option exercise.

16:19 EDT Pacific Biosciences, Invitae amend development and commercialization agreement - In a regulatory filing, Pacific Biosciences of California (PACB) disclosed that on June 24, PacBio entered into an amended and restated development and commercialization agreement with Invitae Corporation (NVTA). "The Amended and Restated Agreement amended and restated the existing Development and Commercialization Agreement, effective as of January 12, 2021, as amended by Amendment No. 1 to Development and Commercialization Agreement, entered into on June 3, 2021, by and between PacBio and Invitae. The parties anticipate that in connection with the Amended and Restated Agreement, PacBio will continue to receive feedback, input and insight from Invitae in connection with the intended development of its new sequencing systems; however, such feedback will not be contractually required and Invitae has no contractual right to participate in decisions regarding the development program for such new sequencing systems. PacBio's development plans for such new sequencing systems will be at PacBio's discretion and pursuant to its own internal processes and programs. Invitae will not be contractually obligated to reimburse PacBio for development costs under the Amended and Restated Agreement. In consideration of the non-refundable Development Costs paid by Invitae to PacBio pursuant to the Original Agreement, PacBio will provide Invitae with credits and discounted pricing in connection with Invitae's anticipated purchase of currently available and in-development sequencing systems. In addition, subject to certain conditions, Invitae will be entitled to most favored pricing for the Company's Sequel IIe systems and certain in-development systems. There can be no assurances that the in-development sequencing systems will continue to be developed, be successfully developed or become available for commercial sale. PacBio and Invitae each may terminate the Amended and Restated Agreement if the other party remains in material breach of the Amended and Restated Agreement following a cure period to remedy such breach," the filing states.

16:16 EDT CBL & Associates initiates 25c per share quarterly dividend - The dividend is payable on July 20, 2022, to shareholders of record as of July 11, 2022. CEO Stephen Lebovitz states: "Our strong operating performance and recent attractive financing activity have further enhanced our substantial cash flow generation and contributed to a cash position of over $335 million as of March 31. We are pleased to share this success through this cash distribution, which is the first step in a broader plan to create and return value to our shareholders."

16:13 EDT Micron falls 4% to $52.90 after results, outlook miss estimates

16:10 EDT Clearway Energy announces CFO Chad Plotkin leaving company - Clearway Energy announced that Chad Plotkin will be stepping down from his position as Executive Vice President and Chief Financial Officer of the Company. Mr. Plotkin will remain with the Company through the filing of the Company's Quarterly Report on Form 10-Q for the three months ended June 30. The Company will conduct a search for a permanent CFO, which will consider internal and external candidates. On an interim basis, the responsibilities of the CFO will be led by Mr. Sotos and the Company's executive leadership team through the successful conclusion of the replacement search process.

16:07 EDT Akebia terminates vadadustat Collaboration and License agreements with Otsuka - Akebia Therapeutics announced that it has executed an agreement to terminate the U.S. and ex-U.S. vadadustat Collaboration and License Agreements with Otsuka Pharmaceutical Co., Ltd. As part of the termination, Otsuka has agreed to pay Akebia a settlement fee of $55M. As a result of the termination of the agreements, Akebia is regaining the rights from Otsuka for vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in the United States, Europe, China, Russia, Canada, Australia, the Middle East, and certain other territories.

16:06 EDT Floor & Decor launches grand opening of West Hartford store on July 7 - Floor & Decor will expand its nationwide footprint when it opens the doors to its newest location in West Hartford, Connecticut on July 7, 2022. The Floor & Decor warehouse store and design center will open with a team of about 50 full-time and part-time associates led by Kim Bova, the new store's Chief Executive Merchant. "Floor & Decor is thrilled to open our doors in West Hartford," said Bova. "We are excited to introduce both Professional customers, as well as Homeowners, to our one-stop solution for their flooring needs with an extensive selection of in-stock, trend-right flooring options. We offer unmatched service and quality flooring at unbeatable prices. With our free design services, we look forward to helping every customer turn their vision into reality."

16:03 EDT Titan Medical appoints Cary Vance as CEO - Titan Medical announced that Cary Vance has been appointed as the company's president and CEO effective July 1. Vance will succeed Paul Cataford, Titan's chair of the board of directors, who has served as interim president and CEO since December 2021. Vance previously served as president and CEO at Xcath Incorporated, a privately held neurovascular robotics company.

15:30 EDT Borr Drilling Limited trading resumes

15:14 EDT Borr Drilling says necessary covenant waivers extended by lenders until July 15 - Borr Drilling Limited refers to its previous communication regarding its ongoing negotiations with creditors to reach mutual agreements to refinance and extend its 2023 maturities and complete such refinancing by June 30, stating: "Significant progress has been made in the negotiations with the target to put in place the right capital structure for the company going forward. A complete solution will require a further equity injection combined with debt repayments, extensions and concessions by the creditors resulting in a robust capital structure that supports a low cash break even and thereby a higher free cash generation. In order to have the required time to conclude full lock-up and commitments from all creditors, the necessary covenant waivers have been extended until 15 July 2022 by the lenders in the bank syndicate. Thus far specific proposals have been received from all creditor groups, some of which have already resulted in agreements in principle. In particular, we have agreed terms in principle for the refinancing of the senior secured bank facility in July 2022 to be funded with a mix of a new credit facility and equity/an asset sale. We will continue to work with all remaining creditors to arrive at an optimized overall financing solution, targeted to be in place by 15 July 2022."

14:49 EDT Rocket Lab says CAPSTONE now passed half-way point of mission's second phase - Rocket Lab USA confirmed its Photon Lunar spacecraft successfully ignited its HyperCurie engine for a fifth time, further carrying NASA's Cislunar Autonomous Positioning System Technology Operations and Navigation Experiment, or CAPSTONE, satellite toward the Moon. "This fifth burn of the HyperCurie engine has propelled CAPSTONE and Photon deeper into space, successfully raising the spacecraft's elliptical orbit. With this latest completed orbit-raising maneuver, Rocket Lab's delivery of CAPSTONE to the Moon on Photon has now passed the half-way point of the mission's second phase with Photon. At the end of this mission phase, Photon will accelerate to more than 24,500 mph to break free of Earth's orbit and deploy CAPSTONE on a ballistic lunar transfer trajectory to the Moon. CAPSTONE will then be controlled by Advanced Space, which owns and operates CAPSTONE on behalf of NASA, to enter an elongated orbit at the Moon called a near rectilinear halo orbit. The final HyperCurie engine ignition on Photon to help set CAPSTONE on its course to the Moon is expected in the coming days," Rocket Lab said.

14:37 EDT Rapid Micro confirms receipt of non-binding proposal from Kennedy Lewis - Rapid Micro Biosystems confirmed that it has received an unsolicited, non-binding proposal from Kennedy Lewis Investment Management LLC to acquire all of the outstanding shares of the Company for $5.00 per share in cash. Consistent with its fiduciary duties and in consultation with its independent advisors, the Rapid Micro Biosystems Board of Directors will carefully review the unsolicited proposal to determine the course of action that it believes is in the best interest of the Company and all Rapid Micro Biosystems shareholders. Rapid Micro Biosystems shareholders do not need to take any action at this time.

14:23 EDT Abstract published on Immunome patient-derived anti-SARS-CoV-2 antibody cocktail - An abstract published in Science Immunology states in part: "Here, we describe an antibody cocktail IMM-BCP-01, that consists of three patient-derived broadly neutralizing antibodies directed at non-overlapping surfaces on the SARS-CoV-2 spike protein... Our pre-clinical data demonstrated that the three antibody cocktail IMM-BCP-01 could be a promising means for preventing or treating infection of SARS-CoV-2 variants of concern, including Omicron BA.1 and BA.2, in susceptible individuals... In summary, we used Immunome's Discovery platform to identify and characterize three potent patient-derived antibodies IMM20190, IMM20184 and IMM20253 based on the antibody function, epitopes and biochemical properties. When combined into the IMM-BCP-01 cocktail, they synergized to neutralize multiple SARS-CoV-2 variants of concern, potently activate Fc-mediated antiviral effector response, and demonstrate antiviral effects in vivo." Inventors on the IMM-BCP-01 patent applications are employees and shareholders of Immunome, the abstract noted. Reference Link

14:01 EDT Meta will debut support for digital collectibles on Facebook - Following its introduction of NFT support on Instagram in the spring, Meta will debut support for digital collectibles on Facebook. Navdeep Singh, a product manager at Meta tweeted screenshots of new support, earlier on Thursday, while saying "We're launching NFTs on Facebook! Excited to share what I've been working on with the world.L Reference Link

13:49 EDT MP Materials added as new long idea at Hedgeye - Hedgeye has added MP Materials as new long idea, with analyst Jay Van Sciver arguing that concerns about competitive entry "appear misplaced," contacts tell The Fly.

13:23 EDT Booz Allen 'strongly disagrees' with DOJ on proposed EverWatch transaction - Booz Allen Hamilton has issued the following statement regarding its proposed EverWatch acquisition, from company spokesperson Jessica Klenk: "For 108 years Booz Allen Hamilton has served clients with integrity and dedication. We are proud of the work we do in service of our government partners to help address some of the toughest problems this country faces. We take very seriously our responsibility to provide the most innovative and effective solutions to meet critical national missions. We strongly disagree with the Department of Justice's characterization of the proposed $440 million, approximately 500-person EverWatch transaction. We believe the acquisition would bring together two companies with complementary capabilities to support our collective national security interests and would enhance competition overall in an industry that is highly competitive. The transaction would accelerate technology development cycles and enable faster delivery of classified software development and analytics for national security clients, including AI, full-spectrum cyber operations, mission analytics, 5G, and TechSIGINT capabilities. Grounded in Booz Allen's culture, values, and commitment to national security missions, this transaction would drive major digital and cyber transformation in the Intelligence Community and beyond, creating a more comprehensive portfolio of offerings to a wider range of intelligence and defense clients. Booz Allen believes the transaction would deliver significant benefits to our government clients and we refute any suggestion that the proposed transaction would harm government agencies or taxpayers."

13:07 EDT Agrico Acquisition Corp trading resumes

13:00 EDT Ocugen 'not just a COVAXIN company,' CEO tells The Fly

13:00 EDT Ocugen CEO says NeoCart, OCU400 trials going 'as expected'

12:47 EDT Comcast's Xfinity Stream app launches on Apple TV 4K, Apple TV HD - Comcast (CMCSA) announced the launch of the Xfinity Stream app on Apple TV 4K (AAPL) and Apple TV HD, giving Xfinity TV customers another option to access their subscription - including all live, on demand, and DVR programming - within the home. Xfinity's redesigned Stream app is launching first on the Apple TV platform, and features a new, more intuitive user interface. The new UI is designed to simplify content discovery through editorial recommendations along with a personalization algorithm that allows customers to continue watching their favorite shows and movies across platforms and devices, Comcast said. "We are always looking for ways to enhance our entertainment experiences as the needs of our customers evolve - whether that's expanding to new platforms, launching new features, or adding more programming options," said Michael DelCiello, Senior Vice President, Strategic Development, Comcast. "With today's launch of the Stream app on Apple TV, our customers now have a new device option for accessing their Xfinity TV subscription in the home, and they will be the first to enjoy a new, streamlined UI designed to make it easier to find something to watch - whether that means getting back to a favorite show or movie, or finding something new."

12:26 EDT Northern Lights Acquisition Corporation (Class A Stock) trading halted, volatility trading pause

12:11 EDT Nikola adjourns Annual Meeting to allow stockholders more time to vote - Nikola Corporation announced that its 2022 Annual Meeting of Stockholders has been adjourned again to July 18, 2022, at 2:00 p.m. Pacific Time to allow stockholders additional time to vote to approve Proposal 2. Nikola stockholders have voted overwhelmingly in favor of Proposal 2, with the exception of the vote of a stockholder who appears to represent more than 85% of the votes against Proposal 2. Approving Proposal 2, which requires a majority of all outstanding common stock to pass, is very important. As of this morning, more than 48% of all outstanding shares have been voted in favor of Proposal 2, leaving less than 2% of outstanding shares to be voted in favor for this proposal to pass. More than 112 million shares have not yet been voted. Nikola has 600 million common shares authorized. As of June 8, 2022, approximately 567 million shares are either issued or reserved for future issuance, leaving Nikola with approximately 33 million shares available for other purposes. That is why Nikola is urging ALL stockholders to vote IMMEDIATELY FOR Proposal 2, which would allow Nikola to increase the authorized number of shares of the Company's common stock to 800 million, providing flexibility to support the growth of the business.

12:01 EDT Acadia Healthcare forms joint venture with Tufts Medicine - Acadia Healthcare Company announced that it has formed a joint venture with Tufts Medicine. The partnership anticipates building a new 144-bed behavioral health hospital at the site of the former Malden Hospital in Malden, Massachusetts, expanding access to critically needed inpatient behavioral health services. The proposed new hospital will offer the latest in inpatient behavioral healthcare and intensive outpatient programs, providing the continuum of care needed to support patients and their families. The new hospital will also serve as a teaching hospital, training students and residents from the Tufts University School of Medicine. The hospital will care for patients of all ages, including the most vulnerable members of the community, especially its adolescent and elderly neighbors. Together, Acadia and Tufts Medicine will invest more than $65M in expanding behavioral health resources in Boston. The new hospital represents the 17th joint venture partnership for Acadia.

12:00 EDT Culp, Inc. falls -15.0% - Culp, Inc. is down -15.0%, or -76c to $4.27.

12:00 EDT Aspen Aerogels rises 14.9% - Aspen Aerogels is up 14.9%, or $1.26 to $9.69.

12:00 EDT ProShares UltraShort Bloomberg Natural Gas rises 16.7% - ProShares UltraShort Bloomberg Natural Gas is up 16.7%, or $5.42 to $37.96.

11:54 EDT Pharming Group NV (ADS) trading halted, volatility trading pause

11:34 EDT Samsung launches Gaming Hub for Samsung Smart TVs - Samsung (SSNLF) is launching Samsung Gaming Hub, the "ultimate home for gaming" on Samsung Smart TVs. "Instantly play the biggest games from Xbox and other top gaming partners with no downloads, storage limits, or console required. Just switch on your TV and play," the company said. Samsung Gaming Hub includes game streaming apps like Xbox Game Pass (MSFT), Nvidia GeForce Now (NVDA), and Google Stadia (GOOGL).

11:00 EDT Burning Rock announces launch of PREVENT study of OverC - Burning Rock Biotech announced the launch of the PREVENT study, China's first prospective interventional study to evaluate the performance of Burning Rock's early cancer detection test, OverC, in the asymptomatic population. The study is expected to enroll 12,500 asymptomatic individuals, to evaluate the performance of the OverC test in detecting 6 cancers. These 6 cancer types cover approximately 50% of China's total cancer incidence, and 62% of cancer mortality. The study is led by Dr. Weimin Li, head of the West China Hospital of Sichuan University.

10:32 EDT Delta Air Lines CEO Bastian provides update to SkyMiles members - CEO Ed Bastian sent an email to SkyMiles members. In the email, Bastian wrote, "...so far in June we've flown over 96% of our scheduled departures, with more than 80% of our flights arriving within 14 minutes of their scheduled arrival time... Things won't change overnight, but we're on a path towards a steady recovery. Steps we've taken include offering more flexibility for your travel plans and adjusting our summer schedule so that when challenges do occur, we can bounce back faster... At the same time, airport procedures are being updated, including earlier boarding to help ensure on-time departures... We've accelerated our hiring as well, bringing on around 15,000 new employees since the start of 2021... And we're continuing to engage with the Federal Aviation Administration on improving processes for air traffic management, which will help minimize delays and cancellations due to inclement weather... Delta has also been investing in digital tools to help you conveniently manage your travel if plans change."

10:27 EDT Fifth Third announces $100B environmental, social finance target through 2030 - Fifth Third announced a new $100 billion environmental and social finance target to be achieved through 2030. The new target is an expansion of the Bank's original $8 billion sustainable finance goal, which was set in 2020. That goal was focused on renewable energy and was recently achieved nearly three years ahead of schedule. Governed by the Fifth Third Environmental and Social Finance Framework, the new target has an expanded scope to include additional environmental eligibility criteria as well as social eligibility criteria to better reflect Fifth Third's overall ESG priorities.

10:25 EDT Entrada Therapeutics Inc trading resumes

10:15 EDT Entrada Therapeutics Inc trading halted, volatility trading pause

10:05 EDT Winnebago appoints Amber Holm as CMO, Sridhar Koneru as CIO - Winnebago Industries announced that Amber Holm will be joining Winnebago Industries as Senior Vice President, Chief Marketing Officer. Sri Koneru is promoted to Senior Vice President, Chief Information Officer and Chad Reece is promoted to Vice President, Government and Industry Relations. In the newly created CMO role, Holm will work strategically to create an even more vibrant Winnebago Industries portfolio by driving marketing and branding efforts at the enterprise level, and engaging the Company's numerous stakeholders more proactively from a communications perspective. Amber will report directly to Winnebago Industries President and CEO, Michael Happe. Holm joins Winnebago Industries effective July 6, 2022, after more than two decades leading marketing and brand management for top consumer brands across multiple industries. Most recently, as Vice President, Brands at Newell Brands, she led the global housewares business, including Rubbermaid, Calphalon, FoodSaver, and Ball Canning, achieving record sales growth and transforming brand positioning, consumer insights, and omnichannel marketing. In his expanded role as CIO, Koneru will partner with company leaders in the development and implementation of digital strategies, including the transformation of customer engagement and interaction, information technologies within products, and internal digital transformation initiatives across the Company. As a member of the Executive Leadership Team, Koneru will continue to report to Bryan Hughes, CFO and Senior Vice President, Finance, IT, and Strategic Planning. As VP, Government and Industry Relations, Reece will be responsible for oversight of ongoing engagement with various outdoor industry related organizations, state and national level government and corporate development contacts, and awareness of key legislation trends and issues. He will also support various corporate relations initiatives and report to Stacy Bogart, SVP, General Counsel, Secretary and Corporate Responsibility. A 34-year veteran of Winnebago Industries, Reece has served in many critical leadership roles, most recently as Director, Corporate Relations where he led enterprise branding and had oversight and management of communications and public relations across Winnebago Industries.

10:02 EDT Middlebury Community Schools adds PowerSchool solutions - PowerSchool announced Middlebury Community Schools in Elkhart County, Indiana added multiple PowerSchool products to its technology stack to fortify its hiring process and financial operations capabilities. MCS has selected PowerSchool Unified Talent Employee Records, PowerSchool Unified Talent Applicant Tracking, and PowerSchool Unified Administration eFinancePlus solutions to modernize their financial and human resources operations, enable more data-informed decisions, and improve overall recruitment and talent management functions.

10:00 EDT Borr Drilling falls -13.4% - Borr Drilling is down -13.4%, or -73c to $4.70.

10:00 EDT Web Street, Inc. rises 9.2% - Web Street, Inc. is up 9.2%, or $4.41 to $52.28.

10:00 EDT Aspen Aerogels rises 22.4% - Aspen Aerogels is up 22.4%, or $1.89 to $10.32.

09:54 EDT SeaWorld parks operating with no reservation requirements, restrictions - SeaWorld is back this summer and guests can visit the parks now with no reservation requirements and no restrictions as the park, rides, attractions, food and beverage, and merchandise outlets are open. Also, guests can experience rides including the all-new Ice Breaker in Orlando, the steepest beyond vertical drop in Florida; Tidal Surge, the world's tallest and fastest screaming swing in San Antonio; and Emperor, California's tallest and fastest floorless dive coaster in San Diego.

09:48 EDT Culp, Inc. falls -10.1% - Culp, Inc. is down -10.1%, or -51c to $4.52.

09:47 EDT PropertyGuru rises 7.5% - PropertyGuru is up 7.5%, or 35c to $5.00.

09:47 EDT Aspen Aerogels rises 27.7% - Aspen Aerogels is up 27.7%, or $2.33 to $10.77.

09:35 EDT Glass Houses Acquisition Corporation (Units) trading resumes

09:31 EDT IPX Stock trading halted, volatility trading pause

09:30 EDT Glass Houses Acquisition Corporation (Units) trading halted, volatility trading pause

09:22 EDT IMAC announces significant traffic growth for The Black Company in Q2 - IMAC Holdings announces significant traffic growth for The Back Company. The Back Space retail chiropractic centers, located in select Walmart stores, generated over 100% visit growth compared to the first quarter. "Our team's effort is evident as we continue to improve systems to support our doctors that delivered over 6,500 visits this calendar quarter," said Jeff Ervin, Chief Executive Officer of IMAC. "The Back Space growth for the second quarter will be a springboard to material revenue during the second half of the year. This growth is significant since we just celebrated our first birthday as a concept and many of our stores opened in 2022." The Back Space's retail healthcare centers specialize in chiropractic adjustments and percussion tool therapies for soft tissue recovery, muscle relaxation and spinal wellness.

09:21 EDT Intuitive, Siemens Healthineers boost integration for Ion Endoluminal procedure - Intuitive (ISRG) announced the U.S. Food and Drug Administration has cleared the integration of a mobile cone-beam CT, CBCT, imaging technology and the Ion Endoluminal System used for robotic-assisted bronchoscopy. Siemens Healthineers (SMMNY) Cios Spin mobile imaging offers integrated functionality with Ion to provide 2D and 3D imaging during procedures to help physicians gain confidence around refining Ion's catheter positioning and help improve biopsy tool placement. Early studies have shown Ion enables a diagnostic yield of approximately 80% in studies with a relatively small average nodule size. 3D imaging is used in peripheral nodule biopsies to confirm that biopsy tools are appropriately placed in a suspicious nodule. An initial single center study demonstrated an improvement in diagnostic yield of up to approximately 10% when the Cios Spin was used with the Ion platform. This new imaging integration could help improve the accuracy of biopsy procedures, a key step in how lung cancer gets diagnosed. Lung cancer kills more people annually than any other cancer and early diagnosis can improve survival rates. The integration enhances a physician's ability to provide minimally invasive lung biopsy with the Ion system, which can give patients answers sooner.

09:18 EDT WidePoint increases working capital line of credit - WidePoint Corporation announced that it has renewed its revolving credit facility of $5 million for working capital. And subsequently increased borrowing capacity of the credit facility by $2 million. The 40% increase expands the total capacity under the facility to $7.0 million subject to maintaining certain financial covenants and collateral.

09:17 EDT NetSol NFS Ascent goes live for Maple Commercial Finance in Australia - NETSOL Technologies has announced the Go-Live of their premier, next-generation platform NFS Ascent Omni Point of Sale, Omni POS, on the cloud for Maple Commercial Finance Pty in Australia. The client is a fast-growing asset finance startup headquartered in Sydney. "It gives me great pleasure in announcing our Go-Live with Maple," said Asad Ghauri, President, NETSOL Technologies, Asia-Pacific and Group MD Europe, NETSOL Technologies Europe. "Maple has opted for Ascent's Omni POS as a broker portal for managing the end-to-end origination process. By implementing on the cloud, they benefitted from a seamless and swift deployment process with the ability to scale on demand in the future. Further, by opting for a cloud native approach, the client benefitted from not having to pay any upfront license fees. This deployment represents the quickest ever implementation in NETSOL's history. We have delivered fast-paced and cost-effective solutions to different local markets across the world. With specific focus on the Australian market, NETSOL ensured its solution for Maple was closely aligned with local requirements and expectations," he added.

09:15 EDT NextPlay Technologies forms strategic partnership with iTAP - NextPlay Technologies announced that HotPlay, the Company's in-game advertising, IGA, unit, has entered into a memorandum of understanding, MOU, with Triplecom Media, iTAP, which sets forth general terms of a proposed partnership between the Company and iTAP. The MOU contemplates a collaboration between the parties, whereby each party will provide certain services and access to certain of their platforms to the other in order to enable each party to provide more comprehensive solutions to their respective customers and users. The parties intend to target India's fast growing online gaming market, where it is estimated approximately 390 million online gamers reside, first, and to expand to additional international markets thereafter. The MOU provides that the collaboration will include the integration of HotPlay's IGA into iTAP's existing entertainment and e-sports content, amongst other things. The collaboration is designed to create an entertainment ecosystem in-line with both organizations' business objectives, tapping into India's fast-growing market. The MOU sets forth the preliminary agreement of the parties related to the proposed partnership; however, it does not obligate either party to proceed with the relationship, and the establishment of the partnership and final terms governing the partnership remain subject to execution of definitive agreements related thereto. Nithinan Boonyawattanapisut, co-CEO of the Company, stated, "The Company sees great opportunity in the Indian market, not only from the size of the market itself but also from the remarkable growth rate of its entertainment segment, particularly in the hyper-casual game space and overall gaming industry. We are optimistic about this strategic collaboration with iTAP's fast-growing OTT platform and the opportunity to enter the Indian market. We believe the recent completion of our goGame asset purchase, our hyper-casual game portfolio, and our HotPlay IGA solution offer a great synergistic value to a comprehensive entertainment platform like iTAP. The integration of HotPlay games and IGA is expected to better position iTAP's entertainment ecosystem in India and augment revenue opportunities through iTAP's rapidly growing user base."

09:13 EDT Avalon GloboCare announces new study featuring 'QTY Code' technology - Avalon GloboCare announced a new study applying artificial intelligence enhanced protein design "QTY Code" technology. The method is expected to accelerate development of therapeutic monoclonal antibodies to treat cancer. The research demonstrates a novel method for quickly predicting the design of so-called "water-loving" or hydrophilic variant structures of the 14 glucose transport membrane proteins in cells, which allows researchers to study the proteins more easily in water. Glucose transport membrane proteins are deregulated in many tumor types and are a potentially important target for cancer therapy. The study was published on June 27, 2022, in QRB Discovery, a peer-reviewed, research journal of biological function, structure and mechanism. The "QTY Code" breakthrough technology, developed by Avalon and the laboratory of Dr. Shuguang Zhang, Ph.D., of MIT's Media lab in Boston, MA, is a protein-design platform that can turn water-insoluble transmembrane receptor proteins into water-soluble proteins, enabling their use in many clinical applications, including drug development. "This new publication with our collaborator, Professor Zhang from MIT, using the QTY code has demonstrated a novel method for quickly predicting the structures of water-soluble versions of glucose transporter proteins, which are proteins important in cancer," said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon. "This is an important discovery as these proteins are difficult to study and so far, poorly understood. These transport proteins, especially those that regulate glucose, play a vital role in the growth of cancer. We believe our method will accelerate our understanding of these proteins and the development of antibodies against them to treat cancer."

09:10 EDT VivoPower announces Tembo EV order from Atlas Iron - VivoPower International announces that its wholly-owned subsidiary, Tembo E-LV, has secured an order for its EV conversion kits from Atlas Iron, a subsidiary of Hancock Prospecting. Kevin Chin, VivoPower's Executive Chairman and Chief Executive Officer, said: "We are delighted to be assisting Atlas Iron in their journey towards electrification and energy efficiency. With the opening of borders across Australia and Southeast Asia, we have been increasing our engagement with other groups and expect to be announcing additional orders in due course."

09:07 EDT Philips incorporates Biodesix's Nodify Lung blood-based testing into its system - Royal Philips (PHG) announced it has teamed up with Biodesix (BDSX) to incorporate the results of Biodesix's Nodify Lung blood-based lung nodule risk assessment testing into Philips Lung Cancer Orchestrator lung cancer patient management system. The incorporation of proteomics data - along with the radiologic and patient history data currently used to determine treatment decisions - can help create diagnostic efficiency for cancer care centers in the management of a growing number of lung nodule cases, via the contextual launch of Biodesix Nodify Lung application within Lung Cancer Orchestrator. "By incorporating Biodesix's Nodify Lung testing, we take another step in leveraging integrated diagnostics from imaging, genomics, and now proteomic results from a simple blood draw to address key moments in the lung cancer patient journey, support care team decision-making, and help health systems learn from their practice patterns in a dashboard view," said Louis Culot, General Manager Oncology Informatics and Genomics at Philips. "We expect the inclusion of Biodesix's ground-breaking technology in Philips Lung Cancer Orchestrator to help drive more confident decisions for the care team, and ultimately benefit patients."

09:07 EDT Inhibrx completes Phase 1 dose escalation for INBRX-105, draws $60M loan - Inhibrx completed Phase 1 dose escalation of INBRX-105, a novel targeted 4-1BB agonist, in combination with Keytruda. It also reported the funding of an additional $60M from its Loan and Security Agreement with Oxford Finance to bring its cash balance to approximately $176M as of June 30. INBRX-105 is a therapeutic candidate based on the single domain antibody platform designed to agonize 4-1BB selectively in the presence of programmed death ligand 1. The study is a first-in-human, Phase 1 trial in patients with locally advanced or metastatic solid tumors. This four-part trial is designed to determine the safety profile and identify the maximum tolerated dose and the recommended Phase 2 dose of INBRX-105 administered in combination with Keytruda. Part 3, dose escalation in combination with Keytruda, has concluded with a total of 30 patients enrolled. INBRX-105 in combination with Keytruda was "reasonably" well-tolerated and durable responses in checkpoint-naive and relapsed refractory patients were observed. These results informed what Inhibrix believes to be the optimal dose level. Part 4 dose expansion cohorts will include a total of approximately 90 patients in five separate cohorts and the company expects to announce initial data from these cohorts in the first half of 2023. Inhibrx has one additional $30M tranche available under the Loan Agreement, which will be available to fund upon the initiation of a potential registration-enabling clinical trial of INBRX-101. To date, the aggregate balance of Inhibrx's outstanding term loans, which mature in January 2027, is $170.0M. The repayment schedule provides for interest-only payments until March 2025 with a potential 12-month extension.

09:03 EDT Edible Garden announces product development agreement with Nutracom - Edible Garden AG announced that it has entered into a product development agreement with Nutracom, an established and trusted developer and contract manufacturer of nutritional products, based in Chesterfield, Missouri. Nutracom operates a state-of-the-art GMP laboratory, and 100,000 square foot cGMP certified, packaging, distribution and warehouse facility. Under the Agreement, the parties plan to develop proprietary lines of Farm to Formula nutraceuticals and other food products, to be distributed through the Edible Garden platform. The new product lines are expected to include vitamins, plant and whey proteins, and other products utilizing next-generation plant ingredients grown and sourced using sustainable methods. Jim Kras, Chief Executive Officer of Edible Garden, commented, "We are excited to embark on this project with Nutracom, given their decades of experience developing and manufacturing nutritional products using the highest quality food ingredients. Specifically, we look forward to launching new lines of nutraceuticals, plant proteins, and other Zero-Waste Inspired products that utilize every part of the plant. Our plan is to develop the best and most efficacious products that harness the full power of the plant. Personally, I have a long history working with Nutracom dating back to my tenure with Nature's Bounty, and I look forward to working with them again on this important initiative."

09:02 EDT Keurig Dr Pepper introduces Intelligentsia Coffee into portfolio - Keurig Dr Pepper and Intelligentsia Coffee announced the launch of Intelligentsia in K-Cup pods for the Keurig brewing system, marking the first time the super-premium coffee brand will be offered to consumers in this format. Chicago-based Intelligentsia has been an American specialty coffee pioneer for more than 25 years, founded by Doug Zell and Emily Mange in 1995.

08:57 EDT Symbotic up as filing shows Walmart as 11.1% holder - Shares of Symbotic (SYM) are up $1.08, or 9%, to $12.95 in pre-market trading after the company filed a prospectus related to the offer and sale from time to time by the selling securityholders identified in this prospectus, or their permitted transferees, of up to an aggregate of 554,976,653 shares of Class A Common Stock. "We will not receive any proceeds from the sale of Class A Common Stock by the Selling Securityholders pursuant to this prospectus," Symbotic stated in the filing. In the filing's listing of 5% holders of Symbotic, the company identifies Walmart (WMT) as a holder of a 11.1% ownership stake. As previously reported, Walmart is the company's largest customer and Symbotic entered into a Master Automation Agreement with Walmart in 2017 to implement systems and restated the agreement in 2022 to implement systems in all of Walmart's 42 regional distribution centers.

08:43 EDT Gaucho Group engages Apollo Art for digital display experiences - Gaucho Group announced its luxury leather goods and accessories brand Gaucho - Buenos Aires has engaged Apollo Art to provide digital display experiences for its Miami, FL, flagship retail store slated to open in July 2022.

08:42 EDT BioLargo engineering subsidiary works with Ultra Safe Nuclear - BioLargo announced that its engineering subsidiary located in Oak Ridge, Tennessee, has been working with Ultra Safe Nuclear to help produce the first prototype fuel production systems for the company's revolutionary new Micro Modular Reactor. A Seattle-based nuclear energy innovator, Ultra Safe Nuclear has invented a "fission battery" - a fourth generation modular nuclear reactor - that can deliver safe, zero-carbon, cost-effective energy anywhere. The MMR uses ceramic-encapsulated nuclear fuel - Fully Ceramic Micro-encapsulated - an extremely rugged and stable fuel with extraordinary high temperature stability. Ultra Safe Nuclear recently opened a facility in Oak Ridge, Tennessee, and reports that it will invest approximately $13 million in the community. The facility is focused on building production systems that can efficiently manufacture the ceramic-encapsulated nuclear fuel used in their reactors. BioLargo Engineering, Science & Technologies has been retained to provide engineering design support, fabrication, and integration for the company's prototype fuel production systems. Thus far, BioLargo has been contracted for work in the range of a half million dollars, to be completed over several months.

08:40 EDT Minerals Technologies elects Motwani to board of directors - Minerals Technologies announced that Rocky Motwani has been elected to its Board of Directors. Motwani is a venture investor and entrepreneur and is currently a Partner and Co-Founder of Mission3, a company that is building and investing in Web3 businesses. He is also Co-Founder of Jiko Group, a technology-based bank holding company.

08:39 EDT Lincoln Educational enters partnership with AkzoNobel Coatings - Lincoln Educational Services Corporation has entered into an agreement with AkzoNobel Coatings. Lincoln Tech's Collision Repair and Refinishing Technology programs across the country will utilize paints and refinish coatings solely from AkzoNobel, as the two organizations strengthen their partnership following the opening of the Kindig Academy at Lincoln Tech in Denver, CO. "AkzoNobel's Sikkens and Lesonal product lines are known as two of the finest brands in the paint and refinish market," says Scott Shaw, Lincoln Tech's President and CEO. "For our students to have access to hands-on experience using these products will be an incredible benefit to them as they train for careers in today's collision repair industry. We are excited and grateful to be able to take our relationship with AkzoNobel to this exciting next level."

08:38 EDT Endo won't make interest payment of $38M due on senior notes on June 30 - In a regulatory filing, Endo International plc reported that the company has elected not to make an interest payment of approximately $38M due on June 30 with respect to the company's outstanding 6.00% Senior Notes due 2028. "Under the indenture governing the senior notes, the company has a 30-day grace period to make the interest payment before such non-payment constitutes an 'event of default' with respect to the senior notes. The company chose to enter the grace period as it continues discussions with certain creditors in connection with the company's evaluation of strategic alternatives. The company's decision to enter the grace period was not driven by liquidity constraints, as it had approximately $1.4B in cash as of March 31, 2022. Accordingly, the company's day-to-day operations will not be impacted by the decision," Endo stated in the filing.

08:37 EDT Muscle Maker's Pokemoto adds Tennessee to portfolio - Pokemoto, Muscle Maker announced the signing of a new Pokemoto franchise agreement for the Gallatin, Tennessee market. This new franchise agreement marks the first entry for Pokemoto into the Tennessee market. Michael Roper, CEO of Pokemoto commented "We're excited to bring Pokemoto to Tennessee with a great franchise partner. We love bringing new franchisees into our Pokemoto Ohana! Over the last few weeks we announced new franchise agreements in Pennsylvania and Texas, now we are adding Tennessee to our expanding portfolio. Pokemoto is in growth mode and our franchise sales team continues to expand the brand via digital targeted marketing efforts, tradeshows, virtual discovery days and more. Once the aforementioned locations open, Pokemoto will have locations operating across 12 states, including Connecticut, Rhode Island, New York, New Jersey, Massachusetts, Virginia, Pennsylvania, Maryland, Mississippi, Florida, Texas and now Tennessee."

08:36 EDT Heritage-Crystal Clean to acquire Patriot Environmental Services - Heritage-Crystal Clean announced it has entered into a definitive agreement to acquire Patriot Environmental Services. Patriot is a provider of environmental services across the Western United States specializing in a wide variety of waste services, including emergency response, industrial services, and OSRO spill response. Patriot provides full-service environmental solutions to a wide variety of end markets, serving customers within manufacturing, agriculture, construction, healthcare, mining, oil & gas, transportation, and utilities markets. From custom on-site services to industrial waste disposal, as well as wastewater treatment, Patriot operates at eighteen locations in the western and southern United States. The transaction, which is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary closing conditions, is expected to close in the third quarter of 2022.

08:35 EDT NeuroSense reports preliminary results from biomarker study of CogniC - NeuroSense announced results from a biomarker study conducted to evaluate the potential of CogniC, NeuroSense's combination drug for the treatment of Alzheimer's disease. NeuroSense's biomarker study identified several biomarkers associated with AD, which indicate CogniC's mechanism of action may be effective in targeting the pathways involved in the disease, such as miRNA dysregulation, lysosomal dysfunction, and impaired autophagy. Additionally, hallmarks of AD were detected, such as increased levels of amyloid-beta and intracellular aggregates of tau protein among the panel of biomarkers evaluated. Preliminary results revealed high levels of TDP-43 in people who suffer from AD, when compared to the healthy control group. These findings provide additional support for TDP-43 pathology as an integral part of AD, reinforcing the growing body of evidence in AD research regarding the role of TDP-43 in neurodegenerative pathologies. TDP-43 has been found in up to 57% of AD cases and aggregates of TDP-43 have been shown to be cytotoxic both in vitro and in vivo. NeuroSense's platform combination therapy technology, the basis of CogniC, has already shown to impact TDP-43 in a Phase IIa clinical trial biomarker study in another neurodegenerative disease, amyotrophic lateral sclerosis. "Having identified these promising biomarkers, which have the potential to be modulated by CogniC, we are now preparing to carry out a clinical proof-of-concept study in conjunction with a leading AD clinic. The study is expected to commence in 2023," stated NeuroSense CEO, Alon Ben-Noon.

08:34 EDT Live Ventures announces acquisition of The Kinetic valued at $26M - Live Ventures Incorporated (LIVE) announced that through its existing subsidiary, Precision Marshall, it has acquired all of the outstanding stock of The Kinetic Co, a 74-year-old, Wisconsin-based company. The transaction, valued at approximately $26M, was financed with a combination of third-party bank and seller debt, a sale-leaseback of real estate, and cash from Live Ventures. Kinetic is a brand name in the production of industrial knives and hardened wear products for the tissue, metals, and wood industries and is known as a one-stop shop for in-house grinding, machining, and heat-treating. "We are excited to add the Kinetic platform to our growing steel manufacturing segment," said Jon Isaac, President and CEO of Live Ventures. "We believe Kinetic's long-tenured family history and culture, combined with its recognized brand name and manufacturing footprint, are a great fit within the Live Ventures model. We look forward to continuing the rich legacy of Kinetic and maintaining its reputation, which comes from 70 plus years of commitment to its customers, employees, and community. We welcome all of the Kinetic employees to the Live Ventures family."

08:34 EDT WPP to acquire Bower House Digital, terms undisclosed - WPP announced it has agreed to acquire the business of Bower House Digital, a marketing technology services agency located in Australia. Bower House Digital will join Ogilvy's global network. Founded in 2017 by Bryan Dobson and Meg Quinn, it employs approximately 80 people across Australia and the Asia Pacific region. The agency designs, builds and deploys digital experiences for clients including Aesop, Bunnings, Bupa, Target and Myer. It specializes in implementing Salesforce Marketing Cloud solutions and was awarded Salesforce's APAC Growth Partner of the Year in 2021.

08:32 EDT MamaMancini's acquires 24% minority interest in Chef Inspirational Foods - MamaMancini's announced it has signed a definitive agreement to acquire a 24% minority interest in Chef Inspirational Foods for an investment of $1.2M , at an implied enterprise value for CIF of $5M. The investment consists of $500,000 in cash and $700,000 in MamaMancini's common stock. "Our investment in a minority interest in CIF brings an experienced, dynamic team which complements our logistics, product development and innovation capabilities with a robust sales presence - all while providing a strong level of vertical integration given T&L is an anchor supplier of CIF," said Carl Wolf, Chief Executive Officer of MamaMancini's. "We expect our investment into CIF to be immediately accretive to net income, while our option to purchase the remainder of the company at a set price provides significant optionality and upside potential. We are excited about the opportunity this acquisition provides to advance our capabilities with a national, innovative, fully integrated food development company with exceptional marketing and sales teams driving incredible penetration across its retail channels.

08:24 EDT 9 Meters Biopharma announces debt facility to support Phase 3 vurolenatide study - 9 Meters Biopharma announced it has entered into a senior secured convertible notes facility with a single lender for up to $70 million that is part of an overall financing strategy to support the continued development of vurolenatide for short bowel syndrome through NDA submission. Under the terms of the agreement, 9 Meters will draw an initial $20 million upon closing of the transaction. The Company has the ability to access up to an additional $50 million in $5-20 million tranches per quarter over an 18-month period, based on meeting certain requirements, including raising additional capital. The notes carry an interest-only period of up to 12 months and will bear interest at a floating rate, which is subject to a floor of approximately six percent. The Company had cash, cash equivalents, and short-term investments of $37 million as of March 31, 2022. Taking into account the initial drawdown of $20 million at closing, the Company would have had pro-forma cash, cash equivalents, and investment balance of $57 million as of March 31, 2022, and an expected cash runway into fourth quarter 2023.

08:22 EDT Equinor announces completed share capital reduction - In line with the objective for the share buy-back programme which was executed by Equinor in three tranches in the period 28 July 2021 until 25 March 2022, the annual general meeting on 11 May 2022 in Equinor ASA decided that the share capital shall be reduced with NOK 205,543,870 from NOK 8,144,219,267.50 to NOK 7,938,675,397.50, by deletion or redemption of total 82,217,548 shares. The creditor deadline for the capital reduction has expired and the capital reduction was completed in the Company Register Center 29 June 2022.

08:20 EDT Osisko announces initial pit resource estimation for San Antonio Property - Osisko Development announces an initial open pit resource estimate for the Sapuchi, Golfo de Oro, California, High Life and Calvario Deposits at its San Antonio Project in Sonora State, Mexico. Project Highlights: Indicated Mineral Resource of 576,000 ounces of gold and 1.37 million ounces of silver; Inferred Mineral Resource of 544,000 ounces of gold and 1.76 million ounces of silver; The 2022 Mineral Resource Estimate covers a portion of the Sapuchi - Cero Verde trend that encompasses five deposits: Sapuchi, Golfo de Oro, California, Calvario and High Life over approximately 2.8 km along strike, a maximum width of 600 metres to a maximum depth of 300 m below surface. Chris Lodder, President of Osisko Development commented, "Osisko Development has made considerable progress at San Antonio in the past year with the construction of the leach pad, near term processing of the stockpile and completion of a drill program to generate this initial resource. The Company believes there is potential to add to the mineral resource through continued exploration and drilling on the property."

08:18 EDT Canadian Apartment Properties appoints Julian Schonfeldt as CIO - Canadian Apartment Properties Real Estate Investment Trust is pleased to announce the appointment of Julian Schonfeldt as Chief Investment Officer effective in the third quarter of 2022. In this role, Mr. Schonfeldt will be responsible for leading CAPREIT's strategic and growth initiatives, including acquisitions, dispositions, capital allocation, investment performance, and communication with key stakeholders. Schonfeldt in his most recent role was Managing Director in the Real Estate Group at RBC Capital Markets.

08:16 EDT NGM Biopharmaceuticals appoints Siobhan Nolan Mangini as President - NGM Biopharmaceuticals announced that Siobhan Nolan Mangini, who has served as the company's Chief Financial Officer, CFO, since July 2020, has been appointed to the additional role of President of NGM Bio. David Woodhouse, Ph.D. will continue to serve as NGM Bio's Chief Executive Officer, CEO. William Rieflin, who has served as Executive Chairman of NGM Bio's Board of Directors since September 2018, will transition to Chairman of the Board effective July 1, 2022. Prior to moving into his role as Executive Chairman, Rieflin served as NGM Bio's CEO and a member of the company's Board of Directors for eight years. In addition to continuing to oversee business development, finance and accounting, and investor relations at NGM Bio, in her new role Nolan Mangini will oversee additional functions, including corporate and product strategy, information technology, and cybersecurity and real estate.

08:14 EDT Xos delivers three battery-electric stepvans to FedEx Ground Operator - Xos announced the delivery of three of its 100% battery-electric stepvans to FedEx Ground Operator Cutone Transport in Ontario, Canada during the month of June 2022. FedEx Ground Operators work as FedEx Corporation independent service providers. With this delivery, Cutone becomes Xos' first Canada-based customer.

08:11 EDT Reneo Pharmaceuticals to present data from Phase 1 REN001 study - Reneo Pharmaceuticals announced that data from the Company's Phase 1 leg immobilization study of REN001 in healthy volunteers has been accepted for presentation at the 17th International Congress on Neuromuscular Diseases being held in Brussels, Belgium July 5-9, 2022. In the study, REN001 was safe and well tolerated. Compared to placebo, REN001 prevented muscle atrophy, promoted faster recovery of muscle strength, and increased transcription of genes involved in mitochondrial biogenesis and function.

08:10 EDT AgileThought names Gonzalo Mones Cason as Chief People Officer - AgileThought announces that Gonzalo Mones Cazon has been appointed as the Company's Chief People Officer, CPO, effective July 4, 2022. Gonzalo Mones Cazon was most recently Head of People at Wildlife Studios.

08:08 EDT Enovis Alcon announces Berry will succeed Hix as CFO - Enovis Corporation (ENOV) announced that Ben Berry, CFO of the Company's business units, will succeed Chris Hix as Chief Financial Officer, effective January 1, 2023. At that time, Hix will transition to an advisory role until his retirement in the fourth quarter of 2023. Previously, Berry spent 18 years in the medical technologies sector with Alcon (ALC), which included its launch as an independent public company.

08:07 EDT Dare announces closing of global license agreement with Organon for XACIATO - Dare Bioscience (DARE) announced that the exclusive license agreement entered into on March 31, 2022 with Organon (OGN), a global women's healthcare company, has become fully effective. Under the agreement, Organon licensed global rights to XACIATO, an FDA-approved medication for the treatment of bacterial vaginosis in females 12 years of age and older. XACIATO received both Qualified Infectious Disease Product and Fast Track designations from the FDA for the treatment of bacterial vaginosis. In connection with the closing, Dare will receive a $10M upfront payment from Organon. Dare is eligible to receive potential milestone payments of up to $182.5M and tiered double-digit royalties based on net sales. XACIATO is expected to be available commercially in the U.S. in Q4 2022. "Bacterial vaginosis is the most common cause of vaginitis worldwide and is estimated to affect approximately 21 million women in the U.S.," said Sabrina Martucci Johnson, President and CEO of Dare. "The Dare team identified bacterial vaginosis as an area in need of new treatment options. We are thrilled to be collaborating with Organon, one of the premier companies in women's health, as we believe Organon's commercial capabilities will ensure that XACIATO reaches the women most impacted by this condition."

08:06 EDT Ildong to license Twist VHH antibody libraries to enhance antibody discovery - Twist Bioscience announced an agreement under which Ildong will license a suite of Twist VHH antibody libraries to use to discover and develop antibodies for applications in immuno-oncology. "This collaboration with Twist moves us closer to our vision of becoming a fully global healthcare company while also continuing to drive novel therapies in South Korea through the expansion of our pipeline," said Hongseok Ban, Ph.D. of Ildong Pharmaceutical. "Access to a selection of Twist's VHH libraries will enable us to complete discovery efforts to select antibody candidates for development as novel immuno-oncology therapies." "We believe our VHH libraries are extremely versatile in their applications developing novel and next generation therapies. Because they are significantly smaller than a traditional human antibody, they can be combined with other technologies, or used on their own for development of effective therapies," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "This VHH library licensing agreement with Ildong is our first collaboration with a South Korea-based company and broadens our presence in the Asia-Pacific region." Under the terms of the agreement, Ildong will license a suite of Twist's VHH libraries for a period of three years and will use the libraries to conduct research and development activities. Twist will receive an upfront payment, annual maintenance fees and additional payments for success-based clinical and regulatory milestones as well as royalties on product sales.

08:05 EDT Nurix Therapeutics announces clearance from US FDA for IND for NX-1607 - Nurix Therapeutics announced that it has received clearance from the U.S. Food and Drug Administration, FDA, for the company's Investigational New Drug, IND, application to expand the ongoing Phase 1 clinical program for NX-1607 into sites in the United States. The Phase 1a/1b study, which currently includes sites in the United Kingdom, is evaluating the first-in-class orally dosed small molecule NX-1607, a Casitas B-lineage lymphoma proto-oncogene inhibitor. The multicenter, open-label Phase 1 dose escalation and expansion trial will evaluate the safety and tolerability of NX-1607 in adults with advanced malignancies which includes a variety of solid tumor indications. "We are pleased with our progress in the clinical evaluation of NX-1607 in the U.K. and clearance of our IND now allows us to advance clinical development at U.S. sites," said Robert Brown, M.D., executive vice president of clinical development of Nurix. "We believe NX-1607 holds tremendous promise as a master immune system orchestrator to address the unmet medical need for patients with a wide range of tumor types. Working with regulatory agencies in the U.S. and abroad builds an important foundation for global development and access. We look forward to sharing initial biomarker data from the Phase 1 trial at an appropriate medical meeting in the second half of 2022."

08:04 EDT Vaxart, hVIVO sign agreement to develop first human omicron challenge model - Vaxart VXRT announced an agreement with hVIVO Services Limited, a subsidiary of Open Orphan under which hVIVO will conduct a characterization study and, if successful, develop a human challenge model based on the Omicron variant of SARS-CoV-2 with the intent to conduct a subsequent Phase II Human Challenge Trial, HCT, of Vaxart's oral COVID-19 vaccine pill candidate. "We are excited at the prospect of testing our vaccine candidates in a human Omicron challenge model particularly given the preclinical data we reported earlier this month that showed two of our COVID-19 vaccine constructs could protect against the Omicron BA.1 variant. A human challenge study of our oral COVID-19 vaccine pill candidate against the Omicron variant of SARS-CoV-2 is the most rapid and direct way to assess the efficacy of this candidate against a highly prevalent viral strain," said Dr. James Cummings, Vaxart's Chief Medical Officer. Following manufacture of the challenge virus, hVIVO will conduct a characterization study to establish a dose of the Omicron challenge virus that will cause a safe and reliable infection in healthy volunteers. The study will enroll healthy male and female volunteers who have previously been vaccinated against or infected with SARS-CoV-2, with no known risk factors for severe COVID-19 and low levels of serum neutralizing antibodies. Subject to the successful completion of the characterization study and receipt of relevant regulatory approvals, the Omicron human challenge trial is expected to begin in 2023.

08:02 EDT Bristow Group signs maintenance agreements for its global AW139 helicopter fleet - Bristow Group has signed long-term, favorable maintenance support agreements with Leonardo Helicopters for airframes and Pratt & Whitney for engines on the company's global fleet of AW139 helicopters. The aggregate buy-in cost is approximately $55M, which will be paid in installments between June and December 2022. In addition to the AW139 agreements, Bristow has also signed long-term maintenance support agreements with Leonardo for the AW189 airframe and with Honeywell for the AW139 avionics suite. Bristow has also signed a long-term maintenance agreement with General Electric for support of AW189 and S-92 engines.

07:57 EDT Acuity Brands jumps 9% to $170.00 after Q3 results beat estimates

07:39 EDT Universal Health drops 7% to $99.00 after FY22 guidance lowered - The company's Q2 EPS forecast also missed estimates.

07:37 EDT Pressure BioSciences to participate in FORCE Family Office webinar - Pressure BioSciences announced the Company's participation in the June 30th Revolutionizing the Development of Plant-Based Food Products webinar, sponsored by FORCE Family Office. This real-time, interactive "Presentation/Q&A Event" will cover the three pressure-based technology platforms of Pressure BioSciences, with strong focus and emphasis on PBIO's Ultra Shear Technology platform.

07:35 EDT Marimed announces filing of final non-offering prospectus - MariMed announced that it has obtained a receipt for its final non-offering, long form prospectus dated June 29, 2022 from the Ontario Securities Commission. Concurrent with its prospectus filing, the Company also received conditional approval from the Canadian Securities Exchange to list the Company's common shares on the CSE under the symbol "MRMD". Listing of the common shares is subject to the satisfaction of certain customary conditions, including the receipt by the CSE of all final documentation. The Company anticipates the dual listing on the CSE to be effective in July of 2022.

07:33 EDT First High-School Education announces RMB4M share repurchase program - First High-School Education announced that its board of directors has authorized a share repurchase program under which the company may repurchase up to RMB4M of its Class A ordinary shares in the form of American depositary shares during a twelve-month period commencing on July 15.

07:33 EDT Constellation Brands enters agreement to eliminate Class B common stock - Constellation Brands announced that following the recommendation of a special committee comprised solely of independent directors, its Board of Directors has approved, and will recommend to shareholders for approval, a proposal to eliminate the company's Class B common stock. The proposed transaction contemplates that each outstanding share of the company's Class B common stock, including those owned by the Sands Family, will be converted into the right to receive one share of Class A common stock plus cash consideration in the amount of $64.64 per share of Class B common stock, or a total amount of $1.5 billion. This represents a 26.5% premium relative to Constellation's Class A common stock closing share price as of June 29, 2022. The Company expects to realize a number of corporate governance and other benefits from the proposed reclassification, including: the elimination of the higher vote Class B common stock, including the associated voting control of the Sands Family, and a reduction in the concentration of voting power; simplification of the Company's equity capital structure to better align the voting rights and interests of all shareholders; broader appeal of its shares to a larger base of investors who prefer single voting class common stock structures; operating cost savings associated with executive salary and certain benefits, as well as administrative savings from maintaining the Class B common stock; rotation of the lead independent director position on the Board at the next available normal cycle opportunity; shift to majority voting in uncontested elections from current plurality standard for its Board of Directors and adoption of a Board anti-pledging policy. In addition, upon completion of the reclassification, Robert and Richard Sands, who currently serve as Executive Chairman of the Board and Executive Vice Chairman of the Board, respectively, will retire from their employment with Constellation Brands in their current executive capacities. Robert Sands will become Non-Executive Chairman of the Board and Richard Sands will continue on as a Board member. It is expected that the Sands Family will continue to be Constellation's largest shareholder following completion of the reclassification. Following the reclassification, the Sands Family will be subject to customary standstill provisions. This reclassification will not be put to a vote at the upcoming 2022 Annual Meeting of Shareholders. Instead, the Company will be seeking shareholder approval of the reclassification at a Special Meeting of Shareholders, to be held following effectiveness of a registration statement to be filed with the Securities and Exchange Commission. The reclassification is subject to the approval of a majority of the outstanding shares of Class A and Class B common stock, voting together as a single class, a majority of the outstanding shares of Class B common stock, and a majority of the issued and outstanding shares of Class A common stock not held by the Sands Family, executive officers of Constellation or directors that hold Class B common stock.

07:31 EDT BioRestorative announces first patient enrolled in Phase 2 trial of BRTX-100 - BioRestorative Therapies announced that the first patient has been enrolled in the Company's Phase 2 clinical trial evaluating the safety and preliminary efficacy of BRTX-100, an autologous bone marrow-derived mesenchymal stem cell targeting chronic lumbar disc disease. The clinical study is being conducted at up to 15 sites in the United States. "Announcing first patient enrollment is our most significant clinical milestone to date and an exciting milestone for BioRestorative's clinical programs overall," said Lance Alstodt, CEO of BioRestorative Therapies. "The initiation of patient enrollment in our study reinforces our commitment to treating back pain and is an important step in our efforts to provide patients with potentially improved therapeutic options to treat chronic lumbar disc disease. In addition, I am very proud of the BRTX team for its timely execution. This truly remarkable accomplishment of first patient enrolled in only 6 months from our trial initiation keeps us on schedule to meet our strategic targets." BioRestorative's Phase 2 trial is a double-blind controlled, randomized study to evaluate the safety and preliminary efficacy of a single dose intradiscal injection of the Company's autologous investigational stem cell-based therapeutic, BRTX-100.

07:29 EDT Gamesquare Esports secures $5M credit facility - GameSquare Esports announces the closing of its previously announced $5.0 million revolving loan facility. The Credit Facility provides GameSquare with access to capital in addition to its current cash on hand as the Company continues its path to profitability while investing in growth and illustrates the strong support that the Company has from its largest shareholders, Goff Capital and the Jones Family, the owners of the Dallas Cowboys. The Credit Facility among GameSquare Esports. GameSquare, Code Red Esports Ltd., NextGen Tech LLC, GCN Inc. and Swingman and Goff & Jones Lending Co, an entity established by Goff Capital, Inc. and Blue & Silver Ventures, Ltd., provides for a revolving loan in the aggregate amount of up to US$5 million for a term of one year, subject to an extension. The Credit Facility may be drawn down by the Borrower, subject to the Company satisfying certain conditions precedent set out therein, including providing a first ranking security interests in the assets of the Guarantors in favour of the Lender prior to the initial advance under the Credit Facility. The Company has not drawn down on the Credit Facility. The Company issued 4,494,286 common share purchase warrants to the Lender. Each Warrant entitles the Lender to acquire one common share in the capital of the Company at an exercise price equal to C$0.14 for a two-year term expiring on June 30, 2024. The Warrants and the underlying Common Shares are subject to a hold period of four months and one day from the date of issuance pursuant to Canadian securities laws as well as applicable hold periods under U.S. securities laws. The Company agreed to issue additional Warrants with respect to any advance made under the Credit Facility which number of Warrants shall equal to the 10% of the Canadian dollar equivalent of such advance divided by the volume weighted average price of the Common Shares prior to the date of the borrowing notice plus a 20% premium to such VWAP. The exercise price on such Warrants shall be an amount equal to the applicable VWAP plus a 20% premium to such VWAP.

07:23 EDT OTC Markets Group welcomes Mayfair Gold to OTCQX - OTC Markets Group announced Mayfair Gold has qualified to trade on the OTCQX Best Market. Mayfair Gold Corp. upgraded to OTCQX from the OTCQB Venture Market.

07:21 EDT Angus Gold completes $5.8M strategic private placement - Angus Gold announced that it has closed its previously announced non-brokered private placement consisting of the sale of 5,057,000 flow-through common shares of the Company at a price of CAD$1.15 per FT Share for total gross proceeds of CAD$5,815,550. In connection with the Offering, funds managed by Delbrook Capital Advisors, acquired 4,387,000 common shares of the Company from subscribers to the Offering and now owns a total of 6,658,200 Common Shares representing 16.2% of the issued and outstanding Common Shares. New Gold exercised its participation right to maintain its pro-rata interest in the Company and purchased 600,000 Common Shares from subscribers to the Offering and now owns a total of 4,100,000 Common Shares representing 9.9% of the issued and outstanding Common Shares. The gross proceeds of the Offering will be used to fund the Company's exploration programs at the Golden Sky project in Ontario. The Company will use an amount equal to the gross proceeds received by the Company from the sale of the FT Shares, pursuant to the provisions in the Income Tax Act, to incur eligible "Canadian exploration expenses" that qualify as "flow-through mining expenditures" as both terms are defined in the Tax Act. The Company will renounce all the Qualifying Expenditures in favour of the subscribers of the FT Shares effective December 31, 2022. Certain directors and officers of the Company subscribed to the Offering for an aggregate of 70,000 FT Shares and the participation of the Insiders in the Offering constitutes a "related party transaction" within the meaning of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions. The Company is relying on an exemption from the formal valuation and minority shareholder approval requirements of MI 61-101 pursuant to section 5.5(a) and section 5.7(1)(a), as the fair market value of the Insiders' participation is not more than 25% of the Company's market capitalization.

07:20 EDT Cara Therapeutics announces results from Phase 2 trial of difelikefalin - Cara Therapeutics announced positive topline results from its Phase 2 proof-of-concept clinical trial evaluating oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica, a nerve disorder characterized by chronic pruritus of the upper to middle back. "We are pleased to have demonstrated clinical proof of concept for oral difelikefalin in the treatment of pruritus associated with notalgia paresthetica," said Joana Goncalves, M.D., Chief Medical Officer at Cara Therapeutics. "These topline results coupled with the results from our other programs support the broad development of oral difelikefalin across disease areas regardless of the underlying cause of pruritus. We look forward to completing our data analyses and discussing next steps with the U.S. Food and Drug Administration." The Phase 2 8-week study was designed to evaluate the efficacy and safety of oral difelikefalin for moderate-to-severe pruritus in approximately 120 patients with NP. Patients were randomized to oral difelikefalin 2 mg taken twice daily versus placebo for 8 weeks, followed by a 4-week active extension period. The primary efficacy endpoint was the change from baseline in the weekly mean of the daily 24-hour Worst Itch-Numeric Rating Scale score at Week 8. Other endpoints included the greater than or equal to4-point responder analysis, itch-related quality of life scores, and safety assessments. Patients treated with oral difelikefalin achieved the primary endpoint with significant improvement observed as early as Week 1 and sustained through Week 8. In addition, a statistically significantly greater proportion of patients treated with oral difelikefalin achieved a greater than or equal to4-point improvement in WI-NRS score at Week 8 vs. placebo. Oral difelikefalin was generally well tolerated with a safety profile consistent with that seen in earlier clinical trials.

07:18 EDT Boralex announces commissioning of 53 MW of wind farms in France - Boralex announced the commissioning of three wind farms for a total capacity of 53 MW. Boralex has an operating capacity of 1.1 GW in France and 2.5 GW worldwide. The wind farms are located in the commune of Louville-la-Chenard, in the Eure-et-Loir department of the Centre-Val de Loire region of France. These commissionings relate to the repowering of two existing wind farms with six wind turbines each and the construction of an extension with seven turbines. The three projects were executed simultaneously and overseen by Boralex's teams. Together, they will produce approximately 138 GWh per year, sufficient to meet the energy needs of some 60,000 French households. Repowering of the Remise de Reclainville wind farm: Commissioning date: May 9, 2022; Wind turbines: 6 Nordex N117; Total capacity after repowering: 14 MW. Repowering of the Evits et Josaphat wind farm: Commissioning date: June 24, 2022; Wind turbines: 6 Nordex N117; Total capacity after repowering: 14 MW. Bois des Fontaines wind farm: Commissioning date: May 12, 2022; Wind turbines: 7 Nordex N117; Total capacity: 25 MW.

07:17 EDT Cellebrite announces availability of Cellebrite Physcial Analyzer Ultra Series - Cellebrite announced the general availability of the Cellebrite Physical Analyzer Ultra Series. The company said, "PA Ultra Series is a revolutionary solution that further empowers investigators to uncover key pieces of case-relevant digital evidence and examine digital data more efficiently, to help secure more convictions, accelerate justice, and close cases faster. PA Ultra Series will significantly boost Cellebrite's Collection & Review offerings as part of the Digital Intelligence suite of solutions. PA Ultra Series will enable investigation teams to leverage an upgraded solution that can process a higher volume of computer, cloud, and mobile data, allow cases to be opened without the need to reparse data and support multiple cases and evidence per device with enhanced location data from a new customizable dashboard. PA Ultra will also enable data enrichment for cryptocurrency, ranging from leading blockchain data platforms to tracking transactions."

07:15 EDT Talaris Therapeutics provides FREEDOM-1 Phase 3 study clinical update - Talaris Therapeutics provided a clinical update on its ongoing Phase 3 FREEDOM-1 study in living donor kidney transplant, LDKT, recipients. To date, Talaris has enrolled 22 donor-recipient pairs in the Phase 3 FREEDOM-1 study of FCR001. Seven patients have been successfully dosed at five different trial sites. All three patients who were dosed more than 12 months prior to the data cutoff date have been successfully weaned off all chronic anti-rejection drugs without evidence of rejection and with stable kidney function. All of these patients, including the first patient who is now 24 months post-transplant, continue to remain off all anti-rejection drugs. Furthermore, all patients treated with FCR001 at least three months prior to the data cutoff date have achieved and maintained T-cell chimerism levels greater than 50% at each of the 3-, 6- and 12-month timepoints post-transplant. The safety profile observed was generally consistent with that expected in patients receiving a kidney transplant and an allo-HSCT. Three cases of low-grade acute graft-versus-host disease were reported, all of which were treatment-responsive and have since resolved. One of these patients is more than 12 months post-transplant and has been successfully weaned off all anti-rejection drugs. As a result of an internal review triggered by the GvHD cases, Talaris has modified its mobilization protocol and added a second post-transplant dose of cyclophosphamide for GvHD prophylaxis. Trial enrollment continues.

07:13 EDT OTC Markets Group welcomes G Mining Ventures to OTCQX - OTC Markets Group announced G Mining Ventures has qualified to trade on the OTCQX Best Market. G Mining Ventures Corp. upgraded to OTCQX from the OTCQB Venture Market.

07:11 EDT Constellation Brands CEO 'pleased' with 'strong start' to fiscal year - "We're pleased with our strong start to the fiscal year. Across the business we're driving consumer demand for our exceptional portfolio of premium, high-end products while executing strong financial and operational performance," said CEO Bill Newlands.

07:10 EDT MediWound names Palash as Chief Operating Officer - MediWound (MDWD)announced the appointment of Tzvi Palash as Chief Operating Officer, COO. Palash will be responsible for leading all operational activities at MediWound. Palash joins MediWound from Enlivex (ENLV), where he leads the design and construction of the new cGMP manufacturing facility.

07:05 EDT Information Services gets 3-year $10M digital deal by Italian government - Information Services Group announced it has been awarded a three-year $10M or EUR 9.4M agreement by the Italian government to help manage and oversee the government's digital transformation program. "This is a significant win for ISG, underscoring our strong track record of supporting digital modernization efforts for our clients," said Michael P. Connors, chairman and CEO of ISG. "We are proud to be a part of Italy's program to leverage technology to improve the accessibility and efficiency of government services for the Italian people, and to build a stronger, more resilient Italy, post-pandemic." Under the new framework contract awarded by Consip, the Italian Public Administration's central IT purchasing body, ISG will provide governance services for various digital transformation initiatives in support of Italy's "Three-Year Plan for Information Technology in the Public Administration" prepared by two government entities: AgID and MITD . ISG will work closely with AgID, Consip and MITD to govern a broad set of initiatives aimed at developing and improving Italy's digital services, including helping the Public Administration's control bodies verify the initiatives are delivering expected value in terms of digitization KPIs and achieving their targets under the three-year plan. ISG has supported the Italian public sector for more than a decade, including governing ICT contracts for the Ministry of the Interior in a relationship that dates back to 2010. The firm also has provided Consip with benchmarking services related to framework agreements for the Public Administration; analysis of cloud strategy scenarios for AgID, and contract monitoring services for INAIL.

07:03 EDT Grayscale files suit against SEC challenging denial of spot Bitcoin ETF request - Grayscale Investments announced that its Senior Legal Strategist, former U.S. Solicitor General, and partner at Munger, Tolles & Olson, Donald B. Verrilli, Jr., filed a petition for review with the United States Court of Appeals for the District of Columbia Circuit on behalf of Grayscale - challenging the decision by the Securities and Exchange Commission to deny conversion of Grayscale Bitcoin Trust to a spot Bitcoin ETF. "Grayscale supports and believes in the SEC's mandate to protect investors, maintain fair, orderly, and efficient markets and facilitate capital formation -- and we are deeply disappointed by and vehemently disagree with the SEC's decision to continue to deny spot Bitcoin ETFs from coming to the U.S. market. Through the ETF application review process, we believe American investors overwhelmingly voiced a desire to see GBTC convert to a spot Bitcoin ETF, which would unlock billions of dollars of investor capital while bringing the world's largest Bitcoin fund further into the U.S. regulatory perimeter. We will continue to leverage the full resources of the firm to advocate for our investors and the equitable regulatory treatment of Bitcoin investment vehicles," said Michael Sonnenshein, Grayscale's CEO.

07:00 EDT Ranger Oil announces bolt-on acquisition of Eagle Ford assets for $110M - Ranger Oil announced additional bolt-on acquisitions of oil and gas assets in the Eagle Ford shale, bringing the total purchase price of transactions signed in the second quarter to approximately $110M, subject to customary adjustments. The combined all cash transactions are expected to be immediately accretive on all key financial metrics and are anticipated to close on or before July 5. Transactions are largely composed of additional working interests in existing Ranger-operated wells along with contiguous producing assets and undeveloped acreage. Purchase price of each transaction at a discount to management's estimated Proved Developed PV-10 value. All cash consideration maximizes accretion to shareholders, while funding through free cash flow maintains Ranger's strong balance sheet. Transactions expected to add production of approximately 1,600 barrels of oil equivalent per day, primarily associated with low-decline, legacy wells. Significant identified cost, marketing and operational synergies through efficient long lateral developments and the use of shared facilities and existing infrastructure. Ranger brought on-line a number of wells during the second quarter at initial production rates greater than 2,500 barrels of oil per day and 3,200 Boe/d including new company records exceeding 2,800 Bbls/d and 4,100 Boe/d.Given the accretive nature of the recent acquisitions and Ranger's organic performance, the company plans to initiate a redetermination of its borrowing base. Pro-forma for the transactions, Ranger anticipates exiting the second quarter producing more than 30 MBbls/d and 42 MBoe/d. Overall for the second quarter, the Company expects to produce near the high-end of the previously announced guidance range.

06:46 EDT Pfizer submits NDA to FDA for PAXLOVID - Pfizer announced the submission of a New Drug Application to the U.S. FDA for approval of PAXLOVID for patients who are at high risk for progression to severe illness from COVID-19. PAXLOVID is currently authorized for emergency use for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. The submission provides the longer-term follow-up data necessary for acceptance and potential approval.

06:40 EDT CGI Inc. achieves USN certification - CGI announced it has achieved UiPath Service Network, or USN, certification for its advanced robotic process automation, or RPA, capabilities.

06:32 EDT Codiak announces data from Phase 1 trials of exoSTING, exoIL-12 - Codiak BioSciences announced platform-validating clinical data from Phase 1 trials of exoSTING and exoIL-12 and plans to advance both candidates into Phase 2 trials. In an open-label Phase 1 trial, exoIL-12 demonstrated a differentiating favorable safety and tolerability profile, with no detectable systemic exposure of IL-12 and no treatment-related adverse events, which has not previously been reported by others with recombinant IL-12. The two patients with cutaneous T cell lymphoma who have been treated each received multiple injections of exoIL-12 and experienced tumor regressions in both injected and non-injected lesions, including a partial response in one patient. In the open-label Phase 1/2 clinical trial evaluating exoSTING as a single agent in patients with late-stage refractory solid tumors, data across all five dose cohorts showed repeat doses of exoSTING were well-tolerated, demonstrated tumor retention with no systemic exposure of the STING agonist, and in a subset of patients, tumor shrinkage was observed in injected and uninjected lesions. "We believe these positive datasets from our two lead programs provide further clinical validation of our engEx Platform and the target profile for our engineered exosome therapeutic candidates. In the studies, we were able to deliver exoSTING and exoIL-12, with repeat dosing, to the tumor with a high level of specificity, no observed systemic exposure or associated toxicity, and an enhanced therapeutic index-while demonstrating tumor shrinkage in both injected and uninjected lesions," said Douglas Williams, Ph.D., President and CEO of Codiak. "STING and IL-12 have been challenging targets that have historically been hampered by very toxic side effects, but we believe our approach may enable best-in-class therapies with favorable safety profiles. Based on these findings, we have identified a recommended Phase 2 dose for both programs. We plan to initiate a Phase 2 study of exoSTING in bladder cancer and a Phase 2 study of exoIL-12 in an expanded group of tumor types in the first quarter of 2023."

06:20 EDT AstraZeneca reports 'positive' results from interim analysis of the AEGEAN trial - AstraZeneca reports "positive" high-level results from a planned interim analysis of the AEGEAN Phase 3 trial showed treatment with AstraZeneca's Imfinzi in combination with neoadjuvant chemotherapy before surgery demonstrated a statistically significant and meaningful improvement in pathologic complete response, or pCR, compared to neoadjuvant chemotherapy alone for patients with resectable non-small cell lung cancer, or NSCLC. A statistically significant improvement in major pathologic response was also observed. The trial will continue as planned to assess the additional primary endpoint of event-free survival, or EFS, to which the company, investigators and participants remain blinded. The safety and tolerability of adding Imfinzi to neoadjuvant chemotherapy was consistent with the known profile for this combination and did not decrease the number of patients able to undergo successful surgery versus chemotherapy alone. These pCR data will be shared with global health authorities and presented at a forthcoming medical meeting when EFS results are available. Susan Galbraith, Executive Vice President, Oncology R&D, said: ''Treating resectable lung cancer early provides the best chance for a cure, yet lung cancer will still recur within five years for the majority of patients despite chemotherapy and successful surgery. Engaging the immune response with Imfinzi both before and after surgery is an exciting new strategy, and we hope these early findings from AEGEAN will lead to improved survival for lung cancer patients in this potentially curative setting."

06:03 EDT Acuity Brands reports net cash from operating activities $165.7M - Net cash from operating activities was $165.7M, a decrease of $150.5M, or 47.6%, in the first nine months of fiscal 2022, compared to the same period in fiscal 2021. During the first nine months of fiscal 2022, the company repurchased 2.3M shares of common stock for a total of $405M.

06:02 EDT Onion Global announces $10M private share repurchase - Onion Global announced that to boost shareholders' confidence, it has entered into a private share repurchase agreement with a third party investor on a privately negotiated basis. Under the terms of the private share repurchase agreement, the company shall purchase and acquire 2,068,900 American depositary shares representing 206,890 Class A ordinary shares from the selling shareholder. The aggregate purchase price of the repurchase is $10M.

05:19 EDT Elbit Systems awarded $548M contract to supply networked warfare capabilities - Elbit Systems announced that it was awarded a contract valued at $548M to supply military-wide multi-domain combat networked warfare capabilities to the Armed Forces of a country in Asia-Pacific. The contract will be performed over a four-year period. Under the contract, Elbit Systems will provide an integrated solution comprising of the Elbit Tiger-X networking middleware; a Torch-X based suite of airborne, land and ship-borne Command and Control applications; as well as advanced waveforms and a wide range of E-LynX Software Defined Radio, or SDR, systems including airborne, vehicular, handheld, and shipborne configurations. The program will include extensive co-development efforts and transfer of know-how. These comprehensive combat networked capabilities are intended to improve operational effectiveness, decision making and interoperability across all domains of operation, platforms and systems. Elbit Systems is engaged in networked warfare programs in several countries, among them Switzerland, Israel, the UK, Sweden, Canada and others.

05:14 EDT Trinseo, GMP announce intention to establish Netherlands recycling plant - Trinseo and GMP Group announced jointly their intended concerted efforts in further unlocking the circularity of polystyrene, or PS. Trinseo and GMP's collaboration aims at providing a framework for cooperation, on an exclusive basis, the construction and operation by GMP of an advanced pretreatment or regeneration plant with a minimum 25kt capacity in the Netherlands. The plant will purify PS waste and deliver high-quality recycled PS pellets via the Super Clean recycling process. The anticipated startup date of the plant in the Netherlands is 2024. There is also an intended execution of a long-term tolling and off-taking agreement. The intended collaboration will see the two companies conduct research into other supply and processing opportunities, utilizing their combined technology expertise to help develop more sustainable solutions.

05:04 EDT Paysafe partners with BetSaracen to enter Arkansas iGaming market - Paysafe announced its entry into the Arkansas mobile sports-betting market through a partnership with BetSaracen, the sportsbook app from Saracen Casino Resort in Pine Bluff, Arkansas, which is owned by the Quapaw Tribe, based in Oklahoma. The partnership's first phase sees BetSaracen integrate Paysafe's Skrill USA digital wallet to enable players to make frictionless deposits and payouts.